Bibliography
- US National Science Foundation . Science and Engineering Indicators. NSF, Arlington, VA, USA (2008).
- Gassmann O , ReepmeyerG, von ZedtwitzM. Leading Pharmaceutical Innovation – Trends and Drivers for Growth in the Pharmaceutical Industry. Springer-Verlag, Berlin, Germany (2004).
- DiMasi JA , GrabowskiHG. The cost of biopharmaceutical R&D. Is biotech different?Managerial Decision Economics28, 469–479 (2007).
- Horrobin DF . Innovation in the pharmaceutical industry.J. Royal Soc. Med.93, 341–345 (2000).
- Gassmann O , ReepmeyerG. Organizing pharmaceutical innovation. From science-based knowledge creators to drug-oriented knowledge brokers.Creativity Innovation Management14, 233–245 (2005).
- Niedergassel B , Curran C-S, Leßing M, Leker J. What drives partners in industry–academia cooperation. Int. J. Tech. Intelligence Planning3, 331–342 (2007).
- Chesbrough HW . Open innovation. A new paradigm for understanding industrial innovation. In: Open Innovation: Researching a New Paradigm. Chesbrough HW, Vanhaverbeke W, West J (Eds). Oxford University Press, Oxford, UK, 1–12 (2006).
- Chesbrough HW . The era of open innovation.MIT Sloan Manag. Rev.35–41 (2003).
- OECD . Open Innovation in Global Networks. OECD Publications, Paris, France (2008).
- Blumenthal D , CausinoN, CampbellE, LouisKS. Relationships between academic institutions and industry in the life sciences – an industry survey.N. Engl. J. Med.334, 368–373 (1996).
- Anonymous . The potential of partnering. Nat. Rev. Drug Discov.7, 187 (2008).
- Mudhar P . Pharma–biotech alliances.Pharmaceutical Technology Europe18, 18–22 (2006).
- Butkus B . Big Pharma’s academic courtship continues with Pfizer–UCSF, Glaxo–IDI research pacts. Biotech Transfer Week. 11 June 2008.
- Niedergassel B , LekerJ. Tacit and explicit knowledge sharing in collaborative R&D projects. Presented at: 18th International Conference on Management of Technology. Orlando, FL, USA, 5–9 April 2009.
- Cyert RM , GoodmanPS. Creating effective university–industry alliances. An organizational learning perspective.Organizational Dynamics25, 45–57 (1997).
- Lopez-Martinez RE , MedellinE, ScanlonAP, SolleiroJL. Motivations and obstacles to university industry cooperation (UIC) – a Mexican case.R&D Management24, 17–31 (1994).
- Fisher R . A marriage of opposites.New Scientist190, 58–61 (2006).
- Herzog P . Open and Closed Innovation – Different Cultures for Different Strategies. Wiesbaden, Gabler, Germany (2008).
- Herzog P , LekerJ. Open vs. closed innovation units. Different cultures for different strategies. Presented at: International Society for Professional Innovation Management Conference. Warsaw, Poland, 17–20 June 2007.
- Herzog P , LekerJ. Open vs. closed innovation strategies, also different innovation cultures? Presented at: R&D Management Conference. Bremen, Germany, 4–6 July 2007.
- Herzog P , LekerJ. Open and closed innovation – different innovation cultures for different strategies.Int. J. Innovation Tech. Management (2009) (In press).
- Niedergassel B , LekerJ. Collaborative R&D Projects. Differences between University–University and University–Industry Partnerships. Presented at: International Society for Professional Innovation Management Conference. Vienna, 21–24 June 2009.
- Hughes B . Pharma pursues novel models for academic collaboration.Nat. Rev. Drug Discov.7, 631–632 (2008).
- Richards P . MIT, Novartis form partnership.MIT Tech. Talk52, 1–6 (2007).
- Alamo-Bethencourt V . GSK’s Harvard cash injection.Nat. Biotech.26, 956 (2008).
Websites
- Accenture. The pursuit of high performance through research and development – understanding pharmaceutical research and development cost drivers (2007) Link.
- World Pharma News. Pfizer Launches Independent Biotherapeutics and Bioinnovation Center. 5 October 2007 www.worldpharmanews.com/content/view/147/30/